参考文献：

1.Bajaj JS，Cordoba J，Mullen KD，et al.Review article:the design of clinical trials in hepatic encephalopathy——an International Society for Hepatic Encephalopathy and Nitrogen Metabolism（ISHEN）consensus statement.Aliment pharmacol Ther，2011，33（7）:739-747.

2.中华医学会消化病学分会，中华医学会肝病学分会.中国肝性脑病诊治共识意见.2013，21（9）:641-651.

3.Weissenborn K，Ennen JC，Schomerus H，et al.Neuropsychological characterization of hepatic encephalopathy.J Hepatol，2001，34（5）:768-773.

4.Montagnese S，Amodio P，Morgan MY.Methods for diagnosing hepatic encephalopathy in patients with cirrhosis:a multidimensional approach.Metab Brain Dis，2004，19（3-4）:281-312.

5.Ciecko-Michalska I，Dziedzic T，Banys R，et al.Does magnetic resonance spectroscopy identify patients with minimal hepatic encephalopathy？Neurol Neurochir Pol，2012，46（5）:436-442.(https://www.daowen.com)

6.Mardini H，Smith FE，Record CO，et al.Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia.J Hepatol，2011，54（6）:1154-1160.

7.Kale RA，Gupta RK，Saraswat VA，et al.Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy.Hepatology，2006，43（4）:698-706.

8.Goldbecker A，Buchert R，Berding G，et al.Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls.J Cereb Blood Flow Metab，2010，30（7）:1384-1393.

9.Katayama K.Ammonia metabolism and hepatic encephalopathy.Hepat Res，2004，30:73-80.

10.Ruggero MA，Argento AC，Heavner MS，et al.Molecular Adsorbent Recirculating System（MARS（（®））removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.Transpl Infec Dis，2013，15（2）:214-218.